E
Edith Borcoman
Researcher at Curie Institute
Publications - 44
Citations - 1195
Edith Borcoman is an academic researcher from Curie Institute. The author has contributed to research in topics: Medicine & Head and neck squamous-cell carcinoma. The author has an hindex of 10, co-authored 35 publications receiving 626 citations. Previous affiliations of Edith Borcoman include PSL Research University & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
Novel patterns of response under immunotherapy.
Edith Borcoman,Yada Kanjanapan,Stéphane Champiat,Shumei Kato,Vincent Servois,Razelle Kurzrock,Sanjay Goel,Philippe L. Bedard,C. Le Tourneau,C. Le Tourneau +9 more
TL;DR: Initially reported in advanced melanoma patients, pseudoprogression occurs when tumor index lesions regress after initial progression, supporting the concept of treating some patients beyond progression, and the classic RECIST remains a reasonable and meaningful method to assess response to immunotherapy in the clinic.
Journal ArticleDOI
Patterns of Response and Progression to Immunotherapy
TL;DR: Classic RECIST remains a reasonable and rational method to assess response to immunotherapy, given the rarity of pseudoprogressions across tumor types and the recent description of hyperprogressions.
Journal ArticleDOI
Hyperprogression under Immunotherapy.
TL;DR: Hyperprogression is a frequent pattern of response under immunotherapy, with a strong impact on patient outcome, and should be stopped early in cases where there is suspicion of hyperprogression.
Journal ArticleDOI
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
TL;DR: The latest evidence and clinical usefulness of pembrolizumab, anti-PD-1 checkpoint inhibitor, in the treatment of advanced cervical cancer is discussed.
Journal ArticleDOI
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis.
Jong Yeob Kim,Keum Hwa Lee,Jeonghyun Kang,Edith Borcoman,Esma Saada-Bouzid,Andreas Kronbichler,Sung Hwi Hong,Leandro Fórnias Machado de Rezende,Shuji Ogino,NaNa Keum,NaNa Keum,Mingyang Song,Claudio Luchini,Hans van Vliet,Jae Il Shin,Gabriele Gamerith +15 more
TL;DR: A meta-analysis of baseline patient factors associated with risks of developing HPD during PD-1/PD-L1 inhibitor therapy found five factors were statistically significantly associated with HPD, and evidence of small-study effect was found in one association.